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The European Respiratory Society’s study on chronic obstructive pulmonary disease (EUROSCOP) is a multicentre 
study performed initially in 12 countries to assess the effect of 3 years’ treatment with inhaled corticosteroids on lung 
function decline in smokers with chronic obstructive pulmonary disease (COPD). It aimed at recruiting 50 subjects 
in 50 European centres. This study discusses the most successful, countrywise, recruitment strategies, an important 
issue since many multicentre European studies may follow in the future. 
The total number of recruited subjects was 2147 in 39 participating centres. In total, at least 25 000 screening 
spirometries were performed, and about 80 000 hospital records were checked. The most effective way of recruiting 
subjects was to screen subjects by spirometry after mass media campaigns (eight out of nine countries). Others used 
workplace screenings and different types of population survey, and only a few centres successfully recruited 
participants by hospital records. 
Inclusion criteria were slightly changed upon low initial accrual rate. Initial surveys in one country, where 2405 
subjects were screened by spirometry, gave an important indication for the change of the inclusion criteria. 
Extension of the upper age limit from 60 to 65 yr considerably improved recruitment, as did a change of the upper 
limit of FEV, from below 80% predicted normal to below 100% predicted normal, while maintaining the FEV,/VC 
ratio below 70%. 
A tremendous effort is needed to recruit individuals with preclinical COPD, but this is certainly feasible with 
adequate strategies adjusted to each country. 
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Introduction 
It has been recognized for years that chronic obstructive 
pulmonary disease (COPD) has a slow onset and progres- 
sion (1). Nowadays, COPD is increasingly common and an 
important cause of death worldwide (2). Especially in the 
early stages, there may be no symptoms, while airflow 
limitation may be present. Nevertheless, at this stage it is 
essential to prevent further deterioration of lung function. 
One important measure in this respect is to stop smoking, as 
this is the main cause of airflow limitation in the 15-20% of 
susceptible smokers (3-7). Cessation of smoking alleviates 
the rapid decline in lung function in initial and advanced 
disease (8,9), but the sustained success rate of even the most 
intensive trial of cessation, the Lung Health Study, is only 
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22% (9). As many smokers are unable to stop smoking, 
despite knowledge of the negative effects on their lungs and 
general health, other measures are necessary to prevent 
morbidity, mortality and the associated high costs of health 
care caused by the progressive loss of lung function. 
The multicentre European Study on COPD (EURO- 
SCOP), directed by the European Respiratory Society 
(ERS) was started in order to assess whether anti- 
inflammatory therapy might improve health in smokers 
with mild to moderate airway obstruction. The study is 
based on the hypothesis and circumstantial evidence that 
inflammation is the main underlying pathophysiological 
mechanism of COPD (10). Smokers who were not able to 
stop smoking within 3 months were randomized in a 
double-blind study to either budesonide (800 pug day - ‘) or 
placebo during a 3-year period (9). To attain a suffi- 
cient number of participants - 500 randomized subjects per 
treatment arm ~ a multicentre study is required. 
To date, only a few multicentre long-term studies 
have been performed in pulmonary medicine. One such 
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multicentre study (The Lung Health study in North 
America) has published its experiences in designing and 
conducting the study (11,12). However, as this was 
performed in only two countries with a common language, 
the EUROSCOP study is even more complicated in this 
respect. Twelve countries with different cultural, economic 
and social backgrounds had to recruit as many participants 
as possible. As it can be expected that in the future more 
multinational studies in the respiratory area will take place, 
especially concerning COPD, we now describe several 
aspects of the recruitment phase in different countries in 
Western Europe. 
Material and Methods 
GENERAL BACKGROUND 
The aim of the EUROSCOP study is to investigate the 
hypothesis that airway inflammation plays an important 
role in the development of COPD. To test this hypothesis, 
the effect of 3 years’ treatment with an inhaled gluco- 
corticosteroid, budesonide, on the decline of post- 
bronchodilator FEV, in cigarette smokers who, despite 
cessation of smoking, continued to smoke after 3 months, 
will be compared to placebo treatment. Budesonide is given 
in a dose of 4OOpg b.i.d via a Turbuhaler (Astra/Draco, 
Lund, Sweden). 
The study is a parallel group, randomized, double-blind, 
multicentre study. Initially, 12 European countries and 47 
centres were involved. The original goal was to recruit 50 
subjects per centre. 
ENTRY CRITERIA 
Final inclusion and exclusion criteria have been presented 
in an earlier report (10). In summary, participants had to be 
between 30 and 65 years of age, smoking more than five 
cigarettes per day at first visit, postbronchodilator FEV, 
had to be between 50 and 100% predicted, prebronchodila- 
tor FEVJVC ~70% reversibility of FEV, < 10% predicted 
normal, and variability in FEV, between visits two and 
three < 15% predicted normal. 
RECRUITMENT PHASE 
The EUROSCOP Steering Committee and the 
EUROSCOP National co-ordinators were responsible for 
the recruitment phase. They remained in close contact with 
the centres. National meetings (one to six times per year, 
varying with country) and international meetings (once per 
year) were arranged in order to exchange ideas and to keep 
a good team spirit. Moreover, ideas were exchanged on 
recruitment strategies in order to keep enrollment high. 
Newsletters were sent four to six times each year to all 
participants with new ideas and results on recruitment 
strategies. 
Recruitment strategies were deliberately not dictated 
before the study, as it was anticipated that the strategies 
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FIG. 1. Total actual recruitment over time in EURO- 
SCOP (solid squares) compared to expected (continuous 
line) recruitment (50 subjects per centre). 
would vary from country to country and from centre to 
centre. 
To follow recruitment in the study, continuous reports 
on the recruitment status of each centre were sent to 
the monitoring centre, which also kept in contact with 
Local Monitors and National co-ordinators. The head of 
the EUROSCOP monitoring centre visited at least one 
national meeting in all countries, and some of the centres, 
personally. Moreover, all centres were visited by the 
supervising lung function co-ordinator of EUROSCOP and 
at regular intervals by the local monitors. 
RECRUITMENT REPORTS 
At the end of the recruitment period a questionnaire was 
sent to every centre on the recruitment methods used in the 
respective centres; it was answered by 29 of the 39 centres. 
The recruitment in two countries is presented in more 
detail. In The Netherlands, all subjects screened for the 
study were consecutively registered during the first part of 
the study. In one centre this registration was performed 
throughout the whole study. These registers have been used 
in the initial phase of recruitment to help in decision 
making on the adjustments of entry criteria. In Finland, a 
special telephone questionnaire was used after advertise- 
ments in the newspapers and data from all phone calls were 
registered. 
Results 
The original goal of the EUROSCOP study was to enroll a 
total of 2500 participants in 12 months. Twelve countries 
started to participate in the EUROSCOP study, and nine 
countries finally recruited subjects. Figure 1 shows the 
actual progress of recruitment which ultimately resulted in 
the enrollment of 2147 participants in 18 months. Thus, 
86% of the recruitment goal has been reached in 50% longer 
time. Centres with a low recruitment rate have been 
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excluded, and final recruitment numbers range from 16 to 
134 per centre. 
As is evident from Fig. 1, early recruitment was slow, 
with an improvement in months 9-12, and a further 
increase during the prolonged recruitment phase between 
months 12 and 18. The final number of recruited subjects, 
2147, divided by 39 centres, gives a mean which is some- 
what higher than the expected 50 participants per centre. 
However, it did not reach the original goal of 2500 partici- 
pants during the run-in period. According to the recruit- 
ment survey, at least 25 000 screening spirometries have 
been performed during the recruitment period, and at least 
80 000 hospital records have been checked. 
It finally appeared that mass media recruitment, includ- 
ing television, radio and newspapers, was the most suc- 
cessful strategy in almost all countries. One exception 
was Denmark, where most participants were derived from 
hospital clinics. The following recruitment strategies were 
applied: 
1. Mass mediu campaign. This was the most efficient way 
of attracting participants to the study (see below for 
different countries). 
2. Workplace screening. In Germany, workplace screening 
did not give the expected number of applicants for the 
study. In Newcastle it worked well, where spirometry 
was performed in smokers in a social security setting in 
collaboration with the health authorities. Screening 
took place over lunch time, and lunch was provided for 
all attenders. Thus, absenteeism from work was no 
problem. 
3. Shopping mall. This was not effective in early trials in 
the Nottingham centre. It took screening of 809 indi- 
viduals to select eight eligible participants, and occupied 
staff time in a very inefficient way. 
4. Hospitul records. Many centres started to screen their 
hospital records, but in most hospitals it became evident 
that very few subjects could be found this way as the 
desired study population most probably had not 
developed symptoms which were severe enough to cause 
them to contact their general practitioner. 
COUNTRIES WITH RECRUITMENT FAILURE 
Three countries dropped out for different reasons. In one 
country, approval of the medical ethics committee came 
late, far beyond approval in other countries, and despite 
local and national mass media campaigns the response was 
very low. In a second country, recruitment was started at 
post offices, where screening was carried out on all attend- 
ants, not only smokers. This huge amount of work finally 
resulted in only a small number of individuals who were 
both eligible and consented to participate. Finally, in a 
third country local organization was not optimal for 
successful recruitment, and factory-related recruitment did 
not work out as expected. 
RECRUITMENT IN REMAINING COUNTRIES 
Figure 2 shows the recruitment in the nine countries finally 
continuing in the study. 
In Belgium, the four centres had a very slow start, and 
during month 10 an extensive mass media campaign 
started, preceded by the organization of the centres to take 
immediate care of the subjects who wanted to be screened in 
the study. A good response was seen in a short time. 
In Denmark, where three centres had very good registers 
of spirometries performed in the hospitals, subjects fulfilling 
the spirometric entry criteria were contacted. In one centre, 
where 300 were called for spirometry check-up, 100 subjects 
showed up and 50 subjects were recruited. This recruitment 
was started early, and the rate of inclusion was relatively 
stable throughout the inclusion period. 
In Finland, early recruitment from hospital records was 
very slow, and after 11 months it was decided at a National 
meeting to start an advertisement campaign to recruit 
subjects. There was an immediate response with very high 
recruitment during one month. Most patients were inter- 
viewed on the telephone, using a simple questionnaire. 
Figure 3 shows the result of 1534 telephone interviews, 365 
individuals being excluded on telephone, not fitting into 
criteria for inclusion. Of the 988 who were immediately 
given an appointment for spirometry, 82% showed up, and 
of these 172 fulfilled all inclusion criteria. Thus, 21% of the 
performed spirometric tests were within the limits for 
inclusion. 
The centres in Italy showed a slow recruitment rate, in 
spite of using various ways to recruit subjects. Mass media 
campaigns of different kinds were tried with varying results. 
However, in one centre 400 subjects were screened by 
spirometry after a newspaper advertisement campaign, and 
43 were included. 
Centres in The Netherlands had an early start trying to 
recruit from hospital records and by posters - for example, 
in hospitals. Soon they started to use newspaper advertise- 
ments, with increasing success. The data are presented 
separately below as they were also used in the evaluation of 
the inclusion criteria, and the changes made during the 
study. 
In Norway, different methods were used. Some centres 
working in occupational medicine checked their earlier 
records as well as performing new spirometry screening 
among the staff. 
In Spain there was a slow onset, due partly to the delay in 
approval by the ethical committee. Some centres used 
advertisements with about 10% inclusion of performed 
spirometries. In one centre, the screening of 5000 hospital 
records showed 300 subjects fulfilling inclusion criteria, of 
which 150 came for spirometry and 35 were included. 
In Sweden, subjects were recruited mainly by means of 
two methods. Newspaper advertisements were used in some 
centres with very good and rapid response in inclusion rate. 
Subjects were also recruited from a population study in the 
Northern part of the country. 
In the United Kingdom, the very early efforts, for 
example, in a shopping mall, were very disappointing. 
Contacts with general practitioners with computerized lists 
of patients were effective in one centre. Some 16 900 
mailshots were sent to patients, with 5000 answers. A 
total of 456 patients were screened, and 21 entered the 
study. Screening in a working place was effective in one 
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FIG. 2. Total actual recruitment over time per country in EUROSCOP, compared to expected (straight line) recruitment 
(50 subjects per centre). 
centre, and newspaper advertisements were effective in two 
centres. 
In summary, and using a questionnaire to assess the 
success rate of different recruitment strategies, 26 out of 39 
centres considered mass media campaigns - especially 
advertisements - to be the most successful strategy. 
Occupational health survey was the most effective for five 
centres. Also, five of 39 centres preferred checking through 
hospital records. Finally, three centres preferred contacts 
with general practitioners. 
Extending the upper age limit to less than 65 years con- 
siderably increased the number of patients in the study, as 
shown in Fig. 4. For the criterion used for inclusion 
(FEV,NC ratio ~70%) the extension from FEV, ~80% 
predicted normal to FEV, ~100% predicted normal in- 
creased the number eligible from 8 to 16% (Fig. 5). The 
major reason for not accepting subjects for the study was a 
normal lung function value. 
Discussion 
USE OF RESULTS OF RECRUITMENT 
STRATEGIES IN THE STUDY 
As many centres complained about the problem of finding 
candidates for the study, the steering committee looked at 
the country that had the quickest start and had collected 
data on all individuals screened. In the four centres 
involved, a total of 2405 patients had been screened. 
Recruitment in this study was successful, although 18 
months were needed instead of 12 months. This is a 
relatively common experience in clinical trials and can be 
anticipated in the secondary agenda of a steering team 
managing a trial. Thus, a rate of 208 participants per month 
had to be enrolled in EUROSCOP according to the 
protocol. It can easily be seen in Fig. 1 that the enrollment 
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FIG. 4. Percentage of screened population, depending on 
age, meeting the inclusion criteria of EUROSCOP in The 
Netherlands. Total number of screened subjects: 2405. 
Numbers below the bars show the absolute number 
included in each age class. 
rate was not uniform. This has been due largely to choice of 
recruitment strategies. Mass media screening has been the 
most successful strategy. As these individuals were screened 
as quickly as possible to prevent ‘dropouts’, the result was 
many eligible participants within 1 or 2 weeks in some 
centres. This also explains the slow enrollment at other 
times. 
The second most successful screening programme was 
occupational health screening and health-care facilities. The 
latter was really successful only in Denmark, thus showing 
different attitudes between countries toward patient referral 
to hospital clinics. This contrasts with the Nocturnal 
Oxygen Therapy Trial, where 78% of the patients were 
enrolled via physicians due to the fact that they had to be 
severely affected patients in need of oxygen. Thus, in studies 
in which mild or pre-clinical disease has to be investigated, 
physician-related accrual can be anticipated to be low. 
Some guidelines for multicentre cross-Europe recruit- 
ment strategies can be derived from our study in mild and 
pre-clinical COPD. Advertisement and articles in news- 
papers appeared to be the best strategy for recruitment of 
patients in most countries (eight out of nine). Participants 
who responded to media strategies have a large component 
of self-motivation as they also have to make contacts 
themselves and travel for their screening. It appears that an 
active, positive attitude is essential for participation in a 
study, especially a long-term one in individuals who are 
even sometimes not known to any doctor as having a 
disease. 
In practice, it was found that a telephone number which 
differs from that of the hospital is essential for quick 
answering, and a sufficient number of telephone lines and 
personnel have to be available after mass media campaigns. 
A screening questionnaire is helpful to exclude those 
individuals who do not fulfill inclusion criteria-for 
example, out of age range, other concomitant serious 
diseases, wrong additional treatment. A quick appointment 
for the first screening is essential to promote enthusiasm in 
the future participant, and is essential for the whole 
study. 
Finally, it can be concluded that a tremendous effort is 
needed to recruit subjects in an early phase of COPD, as is 
the case in the EUROSCOP study. 
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